Here we describe the identification and partial characterization of seven structurally very divergent drugs as efficient inhibitors of invasive growth of lapatinib-resistant HER2 positive breast cancer spheroids and HGSOC ovarian cancer organoids, all functioning via lysosomes. Here, ERBB2 is linked to ovarian cancer.